After first use, the multi-dose vial can be stored in its original carton in the refrigerator for up to 14 days. An additional vial size of Tepylute ®, a ready-to-dilute formulation of thiotepa ...

Credit: Shorla Oncology. Both vial sizes are now available, according to Shorla Oncology. After first use, the multi-dose vial can be stored in its original carton in the refrigerator for up to 14 ...

The differences between PFSs and MDVs (per 1000 doses) is 324.21. MDV: Multidose vial; NA: Not available; PFS: Prefilled syringe. Prefilled syringes (PFSs) have gained market share in the USA ...

Shorla’s new formulation is the only “ready-to-dilute multi-dose vial” of thiotepa for treating breast and ovarian cancer, the press release says. Once opened, it’s stable for 2 weeks when ...

Takeda plans to launch its dengue vaccine, Qdenga, in India by next year through a manufacturing partnership with Biological E, aligning with the 'Make-in-India' initiative. The company aims for ...

has granted approval for 100 mg/10mL multi-dose vial of Tepylute, a ready-to-dilute formulation of thiotepa to treat breast and ovarian cancer, that eliminates the need for reconstitution and may ...

as well as production of single dose vials, which create higher transportation costs and can be up to three times more expensive than multi-dose vials. Zhiqiang Shu, Ph.D, of Berenberg Capital ...

After the first use, the multi-dose vial can be stored in its original carton in the refrigerator for up to 14 days. The US Food and Drug Administration has approved an additional vial size of ...

US-Ireland drugmaker Shorla Oncology has received approval from the US regulator for a new multi-dose vial of Tepylute (thiotepa), a chemotherapy treatment for breast and ovarian cancers. The ...